Benign Prostatic Hyperplasic Devices Market to Blossoming US$ 1,907.36 million at CAGR 7.6% by 2028 - Global Analysis by The Insight Partners

According to our latest study, "Benign Prostatic Hyperplasic Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Product, Procedure Type, and End User," the market is expected to grow from US$ 2,078.78 million in 2021 to US$ 3,467.31 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028.

Benign prostatic hyperplasia (BPH) is a prostate enlargement caused by excessive cell growth in the prostate. BPH is a benign (non-cancerous) prostate condition. Non-cancerous conditions are not usually fatal and do not spread (metastasize) to other body parts. BPH doesn't raise the risk of prostate cancer; unless it manifests symptoms, BPH isn't considered a health issue. Almost all men will have some prostate growth by the age of 70. Getting older, having more belly fat (also known as abdominal obesity), and not getting enough exercise to raise the risk of developing BPH.

Get a Sample PDF Copy of Benign Prostatic Hyperplasic Devices Market at:
https://www.theinsightpartners.com/sample/TIPRE00025704/?utm_source=OpenPR&utm_medium=10411

Leading players formulating the competitive landscape of the global Benign Prostatic Hyperplasic Devices market are:
KARL STORZ SE & Co., KG; Richard Wolf GmbH; Olympus Corporation; Urologix, LLC.; Boston Scientific Corporation; Butterfly; TELEFLEX Incorporated; OmniGuide Holdings, Inc.; Convergent Laser Technologies; ProArc; and Olympus Corporation are a few leading companies operating in the benign prostatic hyperplasic devices market.

Based on procedure type, the benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. In 2022, the transurethral resection of the prostate segment is likely to hold the market's largest share.

As per the end user the Based on end user, the benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment is likely to hold the largest share of the market. Moreover, the clinics segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028, owing to an increase in the number of clinics at a lower cost for treatment, easy accessibility, and flexibility with the short waiting time.

Have Question? Speak to Analyst at:
https://www.theinsightpartners.com/speak-to-analyst/TIPRE00025704/?utm_source=OpenPR&utm_medium=10411

Organic developments such as product launches and approvals are highly adopted strategies by the global benign prostatic hyperplasic devices market players. A few of the recent key market developments are listed below:
In April 2022, Teleflex Incorporated launched the UroLift System in Japan for treating BPH or enlarged prostate. The system was made available for purchase immediately after the launch.
In April 2020, Olympus announced the approval of iTind, its nonsurgical medical device, for the minimally invasive surgery of BPH. This is a temporarily urethral opening device that has been given a De Novo classification by the FDA and is a Class II medical device.

On the basis of geography, the market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East and Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the Rest of South and Central America).

Market players operating in the Benign Prostatic Hyperplasic Devices market also adopt organic strategies such as product launch and expansion to outstretch their footprint and product portfolio worldwide and meet the growing demand.

Order a Copy of Benign Prostatic Hyperplasic Devices Market Share, Strategies and Forecasts 2021-2028 Research Report at:
https://www.theinsightpartners.com/buy/TIPRE00025704/?utm_source=OpenPR&utm_medium=10411

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

This release was published on openPR.